ClinicalTrials.gg
RecruitingNCT05886036Updated Oct 14, 2026

Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial

A Phase 2 interventional study of Biopsy Procedure and Biospecimen Collection in Nodular Lymphocyte Predominant B-Cell Lymphoma, Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma and Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma, sponsored by National Cancer Institute (NCI). Recruiting at 37 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by National Cancer Institute (NCI) · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 9 months later.
Updated Oct 14, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Lymphoma, B-Cell by National Cancer Institute (NCI) — 4 open to participants now, 10 under way, 1 of them phase 3. Lymphoma, B-Cell · National Cancer Institute (NCI).

Planned enrollment
4th of 26
70 · median 32
Started
2024
the only one that year
Phase 2
5 of 27
1 open now
Registered
27th of 27
by date

Among the 27 studies in Lymphoma, B-Cell by National Cancer Institute (NCI), this one is the 4th largest by planned enrollment of the 26 interventional ones that give a count, is the only one that started in 2024, is one of 5 in phase 2, and was the 27th registered.

Lymphoma, B-Cell

889 studies on the registry are indexed under Lymphoma, B-Cell; 289 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

4 of the 27 studies in Lymphoma, B-Cell by National Cancer Institute (NCI) are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 128 (61%) set no upper age limit and 61 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Lymphoma, B-Cell by National Cancer Institute (NCI), or all of them as a file.
02

Study summary

This phase II trial compares mosunetuzumab to the usual treatment (rituximab) for improving survival in patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). Rituximab and mosunetuzumab are monoclonal antibodies. They bind to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Mosunetuzumab may be more effective at extending survival in patients with NLPHL than the usual approach with rituximab.

Read the detailed description

PRIMARY OBJECTIVE:

I. To compare the progression-free survival (PFS) of mosunetuzumab versus rituximab in NLPHL patients.

SECONDARY OBJECTIVES:

I. To compare the safety and antitumor activity of NLPHL patients treated with mosunetuzumab versus rituximab.

II. To evaluate the molecular effects of mosunetuzumab and rituximab on tumor cells and the immune response and identify biomarkers of response or resistance with ribonucleic acid sequencing (RNAseq), whole exome sequencing (WES), immunohistochemistry (IHC) CD20, PD-1, PD-L1, PD-L2.

III. To evaluate tumor microenvironment and peripheral immune status with single-cell ribonucleic acid sequencing (scRNA-seq).

EXPLORATORY OBJECTIVES:

I. To evaluate CD20 expression and correlate with response. II. To evaluate the dynamic molecular response of NLPHL patients treated with rituximab or mosunetuzumab with circulating tumor deoxyribonucleic acid (ctDNA).

III. To evaluate the safety and efficacy (including tumor response, immune response, and overall survival) of the crossover patients.

IV. To assess the association of baseline fludeoxyglucose F-18 (FDG)-positron emission tomography/computed tomography (PET/CT) measurements including metabolic tumor volume (MTV) and maximum standardized uptake value (SUVmax), in combination with other risk factors, with PFS and overall survival (OS) in patients with lymphocyte-predominant Hodgkin lymphoma treated with mosunetuzumab or rituximab.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive mosunetuzumab subcutaneously (SC) on days 1, 8, and 15 of cycle 1 and day 1 of subsequent cycles. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patients who experience progressive disease (PD) will be permitted to crossover to arm II at week 12. Patients also receive FDG and undergo PET/CT at baseline and end of treatment. Patients who are positive at pre-treatment bone marrow biopsy also receive FDG and undergo PET/CT on study. Patients also undergo bone marrow biopsy and tissue biopsy at baseline, and blood sample collection throughout the trial. Patients may also undergo bone marrow biopsy and tissue biopsy at end of treatment.

ARM II: Patients receive rituximab intravenously (IV) on day 1 and rituximab and hyaluronidase human SC on days 8, 15, and 22 of each cycle. Cycles repeat every 28 days for up to 2 cycles 8 weeks apart in the absence of disease progression or unacceptable toxicity. Patients may receive rituximab IV on days 8, 15, and 22 of each cycle if rituximab and hyaluronidase human is not available. Patients who experience PD will be permitted to crossover to arm I at week 12. Patients also receive FDG and undergo PET/CT at baseline and end of treatment. Patients who are positive at pre-treatment bone marrow biopsy also receive FDG and undergo PET/CT on study. Patients also undergo bone marrow biopsy and tissue biopsy at baseline, and blood sample collection throughout the trial. Patients may also undergo bone marrow biopsy and tissue biopsy at end of treatment.

After completion of study treatment, patients are followed up every 6 months for 2 years.

03

Conditions studied

  • Nodular Lymphocyte Predominant B-Cell Lymphoma
  • Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma
  • Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histopathologically confirmed diagnosis of NLPHL as confirmed by local pathologist's expert review.

    • Untreated NLPHL: stage IB to IV according to Cotswolds. The proportion of patients with stages I or II treated with consolidative radiotherapy will be capped at 40%.
    • Previously treated NLPHL, any stage.
    • According to the treating physician, the patient should not be observed and needs therapy, notably because of B-symptoms (unexplained fever [temperature > 38 degrees Celsius (> 100.4 degrees Fahrenheit)], weight loss [unexplained loss of > 10 percent of body weight over the past six months], or drenching night sweats), symptomatic nodal or extranodal disease, or patient preferences.
  • Patients must have according to the Lugano/Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC) classification.
  • Age >= 18 years. Because no dosing or adverse event (AE) data are currently available on the use of mosunetuzumab in patients \< 18 years of age, children are excluded from this study.
  • performance status =\< 2 ( >= 60%).
  • >= 1,000/mcL.
  • >= 100,000/mcL.
  • Total =\< 1.5 institutional (ULN), except in patients with Gilbert's syndrome as defined by > 80% unconjugated bilirubin.
  • (AST)(serum glutamic-oxaloacetic transaminase [SGOT])/alanine transaminase (ALT)(serum glutamic-pyruvic transaminase [SGPT]) =\< 3 x institutional ULN.
  • (GFR) >= 40mL /min= GFR (mL/Min/1.73 m\^2) * body surface area (BSA)/1.73.
  • -infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
  • For patients with evidence of chronic virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
  • Patients with a history of virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
  • Patients with a prior or concurrent whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the regimen are eligible for this trial.
  • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the Functional Classification. To be eligible for this trial, patients should be class 2B or better.
  • The effects of mosunetuzumab on the developing human fetus are unknown. For this reason and because other therapeutic agents used in this trial are known to be teratogenic, women of and men must agree to use adequate (hormonal and/or barrier method of birth control; abstinence) (both hormonal and barrier method of birth control are required for participants in Canada) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men and women treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 3 months after completion of mosunetuzumab administration and 12 months after completion of rituximab administration.
  • Ability to understand and the willingness to sign a written document. Legally authorized representatives may sign and give informed consent on behalf of study participants.

Exclusion criteria

Exclusion Criteria:

  • Classical Hodgkin lymphoma (cHL) or composite lymphoma.
  • Active transformed NLPHL, concerns of the treating physician of an active occult transformation or concerns of the treating physician that the patient needs cytotoxic therapy. Participants with a history of transformed NLPHL in complete remission for at least 2 years since completion of cytotoxic therapy are eligible
  • NLPHL relapse less than 6 months after rituximab or rituximab-containing therapy.
  • Patients who have not recovered from AEs due to prior anticancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia.
  • Patients who are receiving any other agents.
  • Patients with central nervous system (CNS) involvement as a result of lymphoma.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to mosunetuzumab or rituximab.
  • Patients with uncontrolled intercurrent illness or any other significant condition(s) that would make participation in this protocol unreasonably hazardous.
  • Pregnant women are excluded from this study because there is an unknown but potential risk for AEs in nursing infants secondary to treatment of the mother with mosunetuzumab; breastfeeding should be discontinued if the mother is treated with mosunetuzumab or rituximab. These potential risks may also apply to other agents used in this study.
  • Prior allogeneic stem cell or solid organ transplantation.
  • Participants who have received a live, attenuated vaccine within 4 weeks before first dose of study treatment or anticipation that such a live, attenuated vaccine will be required during the study. Participants must not receive live, attenuated vaccines (e.g., FluMist [registered trademark]) while receiving study treatment and after the last dose until B-cell recovery to the normal ranges. Killed vaccines or toxoids should be given at least 4 weeks prior to the first dose of study treatment to allow development of sufficient immunity.
  • Any other anti-cancer therapy, whether investigational or approved, including but not limited to chemotherapy, within 4 weeks or 5 half-lives of the drug, whichever is shorter, prior to initiation of study treatment.
  • Evidence of any significant, concomitant disease that could affect compliance with the protocol or interpretation of results as judged by the investigator, including, but not limited to:

    • Significant cardiovascular disease (e.g., class III or IV cardiac disease, myocardial infarction within the previous 6 months, unstable arrhythmia, or unstable angina).
    • Significant pulmonary disease (such as obstructive pulmonary disease or history of bronchospasm).
    • Current or past history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease.
    • Participants with a history of stroke who have not experienced a stroke or in the past 1 year and have no residual neurologic deficits as judged by the investigator are allowed.
    • Participants with a history of epilepsy who have had no seizures in the past 2 years with or without anti-epileptic medications can be eligible only for the expansion cohort.
    • History of confirmed progressive multifocal leukoencephalopathy (PML).
  • Participants with infections requiring IV treatment with antibiotics or hospitalization (grade 3 or 4) within the last 4 weeks prior to enrollment or known active bacterial, viral (including SARS-CoV-2), fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment.
  • Systemic medications (including, but not limited to, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents) within 2 weeks prior to first dose of study treatment.
  • Known or suspected chronic active Epstein-Barr virus (EBV) or cytomegalovirus (CMV) infection.
  • Known or suspected history of hemophagocytic lymphohistiocytosis (HLH).
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Arm I (Mosunetuzumab)

    Patients receive mosunetuzumab SC on days 1, 8, and 15 of cycle 1 and day 1 of subsequent cycles. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patients who experience PD will be permitted to crossover to arm II at week 12. Patients also receive FDG and undergo PET/CT at baseline and end of treatment. Patients who are positive at pre-treatment bone marrow biopsy also receive FDG and undergo PET/CT on study. Patients also undergo bone marrow biopsy and tissue biopsy at baseline, and blood sample collection throughout the trial. Patients may also undergo bone marrow biopsy and tissue biopsy at end of treatment.

    Procedure: Biopsy Procedure · Procedure: Biospecimen Collection · Procedure: Bone Marrow Biopsy · Procedure: Computed Tomography · Other: Fludeoxyglucose F-18 · Biological: Mosunetuzumab · Procedure: Positron Emission Tomography

  • Active comparator
    Arm II (Rituximab, Rituximab and hyaluronidase human)

    Patients receive rituximab IV on day 1 and rituximab and hyaluronidase human SC on days 8, 15, and 22 of each cycle. Cycles repeat every 28 days for up to 2 cycles 8 weeks apart in the absence of disease progression or unacceptable toxicity. Patients may receive rituximab IV on days 8, 15, and 22 of each cycle if rituximab and hyaluronidase human is not available. Patients who experience PD will be permitted to crossover to arm I at week 12. Patients also receive FDG and undergo PET/CT at baseline and end of treatment. Patients who are positive at pre-treatment bone marrow biopsy also receive FDG and undergo PET/CT on study. Patients also undergo bone marrow biopsy and tissue biopsy at baseline, and blood sample collection throughout the trial. Patients may also undergo bone marrow biopsy and tissue biopsy at end of treatment.

    Procedure: Biopsy Procedure · Procedure: Biospecimen Collection · Procedure: Bone Marrow Biopsy · Procedure: Computed Tomography · Other: Fludeoxyglucose F-18 · Procedure: Positron Emission Tomography · Biological: Rituximab · Biological: Rituximab and Hyaluronidase Human

Interventions

  • ProcedureBiopsy Procedure

    Undergo tissue biopsy

    Also known as: Biopsy, BIOPSY_TYPE, Bx

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • ProcedureBone Marrow Biopsy

    Undergo bone marrow biopsy

    Also known as: Biopsy of Bone Marrow, Biopsy, Bone Marrow

  • ProcedureComputed Tomography

    Undergo PET/CT

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography

  • OtherFludeoxyglucose F-18

    Receive FDG

    Also known as: 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18

  • BiologicalMosunetuzumab

    Given SC

    Also known as: Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A, BTCT 4465A, BTCT-4465A, BTCT4465A, CD20/CD3 BiMAb BTCT4465A, Lunsumio, Mosunetuzumab-axgb, RG 7828, RG-7828, RG7828, RO7030816

  • ProcedurePositron Emission Tomography

    Undergo PET/CT

    Also known as: Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT

  • BiologicalRituximab

    Given IV

    Also known as: ABP 798, ABP-798, ABP798, BI 695500, BI-695500, BI695500, Blitzima, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT P10, CT-P10, CTP10, GP 2013, GP-2013, GP2013, IDEC 102, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, IDEC102, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF 05280586, PF-05280586, PF05280586, Riabni, Ritemvia, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar GP2013, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-blit, Rituximab-pvvr, Rituximab-rite, Rituximab-rixa, Rituximab-rixi, Rixathon, Riximyo, RTXM 83, RTXM-83, RTXM83, Ruxience, Truxima

  • BiologicalRituximab and Hyaluronidase Human

    Drug page: Rituximab and Hyaluronidase HumanStudies of Rituximab and Hyaluronidase HumanRituximab and Hyaluronidase Human pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given SC

    Also known as: Rituxan Hycela, Rituximab Plus Hyaluronidase, Rituximab/Hyaluronidase, Rituximab/Hyaluronidase Human

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS) time

    Will be assessed according to the Lugano/Lymphoma Response to Immunomodulatory Therapy Criteria classification. The overall PFS curve will be displayed by treatment arm using the Kaplan-Meier (KM) method, and statistical comparisons will be performed by a log-rank test.

    Time frame: Time from the date of randomization to the first objective documentation of disease progression or death due to any cause, assessed up to 2 years

Secondary outcomes

  1. Objective response

    The count and incidence rate of the response categories will be summarized for the overall population and by each treatment arm with a 95% exact confidence intervals. Comparison between treatment arms will be performed by a chi-squared test.

    Time frame: At week 12 and end of treatment

  2. Duration of response

    Will be displayed by treatment arm using the KM method, and statistical comparisons will be performed by a log-rank test.

    Time frame: Time from the first date of partial or complete response until death or the assessment date of disease progression, assessed up to 2 years

  3. Overall survival (OS)

    Will be displayed by randomized treatment arm using the KM method, and statistical comparisons will be performed by a log-rank test.

    Time frame: Time from the date of randomization to death due to any cause, assessed up to 2 years

Other outcomes

  1. CD20 expression

    CD20 expression will be evaluated and correlated with overall response rate, complete remission rate at end of treatment, and 2-year progression free survival.

    Time frame: Assessed up to 2 years

  2. Molecular effects of mosunetuzumab and rituximab on tumor cells and the immune response

    Will assess the molecular effects of mosunetuzumab and rituximab on tumor cells and the immune response and identify biomarkers of response or resistance (objective response rate, complete remission rate at end of treatment, and 2-year PFS) with ribonucleic acid sequencing, whole exome sequencing, immunohistochemistry CD20, PD-1, PD-L1, and PD-L2.

    Time frame: Assessed up to 2 years

  3. Tumor microenvironment and peripheral immune status

    Will be assessed by single-cell ribonucleic acid sequencing.

    Time frame: Assessed up to 2 years

  4. Dynamic molecular response of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) patients

    Will evaluate the dynamic molecular response of NLPHL patients treated with rituximab or mosunetuzumab with circulating tumor deoxyribonucleic acid.

    Time frame: During the first 7 weeks of treatment and at the end of treatment

  5. Incidence of adverse events

    Will be assessed by tumor response, immune response, and overall survival of the crossover patients.

    Time frame: Assessed up to 2 years

  6. Fludeoxyglucose F-18 positron emission tomography/computed tomography (FDG-PET/CT) measurements

    Will assess the association of FDG-PET/CT measurements, including metabolic tumor volume and maximum standardized uptake value, in combination with other risk factors, with PFS and OS in patients with lymphocyte-predominant Hodgkin lymphoma treated with mosunetuzumab or rituximab.

    Time frame: At baseline

07

Study locations

34 of 37 sites recruiting
  • City of Hope Comprehensive Cancer Center
    Duarte, California 91010, United States
    Recruiting
  • UM Sylvester Comprehensive Cancer Center at Aventura
    Aventura, Florida 33180, United States
    Recruiting
    • Site Public Contact · Contact954-461-2180
    • Michele Stanchina · Principal investigator
  • UM Sylvester Comprehensive Cancer Center at Coral Gables
    Coral Gables, Florida 33146, United States
    Recruiting
    • Site Public Contact · Contact305-243-2647
    • Michele Stanchina · Principal investigator
  • UM Sylvester Comprehensive Cancer Center at Coral Springs
    Coral Springs, Florida 33065, United States
    Recruiting
    • Site Public Contact · Contact305-243-2647
    • Michele Stanchina · Principal investigator
  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach
    Deerfield Beach, Florida 33442, United States
    Recruiting
    • Site Public Contact · Contact305-243-2647
    • Michele Stanchina · Principal investigator
  • UM Sylvester Comprehensive Cancer Center at Doral
    Doral, Florida 33166, United States
    Recruiting
  • UM Sylvester Comprehensive Cancer Center at Hollywood
    Hollywood, Florida 33021, United States
    Recruiting
    • Site Public Contact · Contact305-243-2647
    • Michele Stanchina · Principal investigator
  • University of Miami Miller School of Medicine-Sylvester Cancer Center
    Miami, Florida 33136, United States
    Recruiting
    • Site Public Contact · Contact305-243-2647
    • Michele Stanchina · Principal investigator
  • UM Sylvester Comprehensive Cancer Center at Kendall
    Miami, Florida 33176, United States
    Recruiting
    • Site Public Contact · Contact305-243-2647
    • Michele Stanchina · Principal investigator
  • University of Miami Sylvester Comprehensive Cancer Center at Sole Mia
    North Miami, Florida 33181, United States
    Recruiting
  • UM Sylvester Comprehensive Cancer Center at Plantation
    Plantation, Florida 33324, United States
    Recruiting
    • Site Public Contact · Contact305-243-2647
    • Michele Stanchina · Principal investigator
  • Emory University Hospital/Winship Cancer Institute
    Atlanta, Georgia 30322, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University of Kansas Cancer Center
    Kansas City, Kansas 66160, United States
    Recruiting
  • University of Kansas Cancer Center-Overland Park
    Overland Park, Kansas 66210, United States
    Recruiting
  • University of Kansas Hospital-Westwood Cancer Center
    Westwood, Kansas 66205, United States
    Recruiting
  • University of Kansas Cancer Center - Briarcliff
    Kansas City, Missouri 64116, United States
    Recruiting
    • Site Public Contact · Contact913-588-3671
    • Marc S. Hoffmann · Principal investigator
  • University of Kansas Cancer Center - North
    Kansas City, Missouri 64154, United States
    Recruiting
  • University of Kansas Cancer Center - Lee's Summit
    Lee's Summit, Missouri 64064, United States
    Recruiting
  • University of Kansas Cancer Center at North Kansas City Hospital
    North Kansas City, Missouri 64116, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Memorial Sloan Kettering Basking Ridge
    Basking Ridge, New Jersey 07920, United States
    Recruiting
    • Site Public Contact · Contact212-639-7592
    • Raphael E. Steiner · Principal investigator
  • Memorial Sloan Kettering Monmouth
    Middletown, New Jersey 07748, United States
    Recruiting
    • Site Public Contact · Contact212-639-7592
    • Raphael E. Steiner · Principal investigator
  • Memorial Sloan Kettering Bergen
    Montvale, New Jersey 07645, United States
    Recruiting
    • Site Public Contact · Contact212-639-7592
    • Raphael E. Steiner · Principal investigator
  • Memorial Sloan Kettering Commack
    Commack, New York 11725, United States
    Recruiting
    • Site Public Contact · Contact212-639-7592
    • Raphael E. Steiner · Principal investigator
  • Memorial Sloan Kettering Westchester
    Harrison, New York 10604, United States
    Recruiting
    • Site Public Contact · Contact212-639-7592
    • Raphael E. Steiner · Principal investigator
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
    Recruiting
    • Site Public Contact · Contact212-639-7592
    • Raphael E. Steiner · Principal investigator
  • Memorial Sloan Kettering Nassau
    Uniondale, New York 11553, United States
    Recruiting
    • Site Public Contact · Contact212-639-7592
    • Raphael E. Steiner · Principal investigator
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27157, United States
    Recruiting
    • Site Public Contact · Contact336-713-6771
    • Rakhee Vaidya · Principal investigator
  • University of Cincinnati Cancer Center-UC Medical Center
    Cincinnati, Ohio 45219, United States
    Recruiting
    • Site Public Contact · Contactcancer@uchealth.com · 513-584-7698
    • Zulfa Omer · Principal investigator
  • Ohio State University Comprehensive Cancer Center
    Columbus, Ohio 43210, United States
    Recruiting
    • Site Public Contact · ContactJamesline@osumc.edu · 800-293-5066
    • Yun Choi · Principal investigator
  • University of Cincinnati Cancer Center-West Chester
    West Chester, Ohio 45069, United States
    Recruiting
    • Site Public Contact · Contactcancer@uchealth.com · 513-584-7698
    • Zulfa Omer · Principal investigator
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
    Recruiting
  • UPMC Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • UT MD Anderson Cancer Center
    Houston, Texas 77030, United States
    Recruiting
  • Huntsman Cancer Institute/University of Utah
    Salt Lake City, Utah 84112, United States
    Recruiting
  • University of Virginia Cancer Center
    Charlottesville, Virginia 22908, United States
    Recruiting
  • VCU Massey Comprehensive Cancer Center
    Richmond, Virginia 23298, United States
    Recruiting
    • Site Public Contact · ContactCTOclinops@vcu.edu · 804-628-6430
    • Bruce O. Hough · Principal investigator
  • University Health Network-Princess Margaret Hospital
    Toronto, Ontario M5G 2M9, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — "NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page."

Data sharing details ↗ · grants.nih.gov

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Oct 2028, 57 months after the start.

Of 94 non-industry phase 2 interventional studies under Lymphoma, B-Cell, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 81. This study's planned 57 months is close to that.

Counting every sponsor, half of 120 studies reached it within 53 months; a quarter within 34 and three quarters within 73.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Oct 2026 → Oct 2028 and completion Oct 2026 → Oct 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2023
First posted
Jun 2, 2023
StartActual
Jan 23, 2024
Primary completionEst.
Oct 31, 2028was Oct 2026
CompletionEst.
Oct 31, 2028was Oct 2026
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 31, 2026→Oct 31, 2028
Oct 14, 2026
Study completion
Oct 31, 2026→Oct 31, 2028
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Primary completion Oct 31, 2026→Oct 31, 2028
    Study completion Oct 31, 2026→Oct 31, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05886036
Responsible party
Sponsor
First posted
Jun 2, 2023
Start date
Jan 23, 2024
Primary completion
Oct 31, 2028 (estimated)
Completion
Oct 31, 2028 (estimated)
Last update
Oct 14, 2026

Study contacts

Raphael E Steiner
principal investigator · University of Texas MD Anderson Cancer Center LAO

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mosunetuzumab

Start the discussion